ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...
Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...
Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming quarters. The rising adoption of ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made ...
The Omnipod 5 System consists of a tubeless wearable Pod, the Omnipod 5 mobile app, and the Dexcom G6 Continuous Glucose Monitoring System. The Food and Drug Administration (FDA) has cleared the ...
The correction is related to the Omnipod 5 Controller charging port (USB-C port) or cable (USB cable) melting, deforming, or discoloring. Insulet Corporation has voluntarily issued a Medical Device ...
Insulet racked up another quarter of strong performance and finished the full year very close to our estimates; we’re leaving our fair value estimate intact. Fourth-quarter revenue increased 26% in ...
Patients with type 1 diabetes (T1D) who used the Omnipod 5 Automated Insulin Delivery (AID) System saw significant improvements in psychosocial outcomes, including diabetes distress and hypoglycemic ...
Insulet Corporation’s PODD rapid commercial expansion of its Omnipod platform is poised to help it grow in the upcoming quarters. The rising adoption of Omnipod 5 also presents a promising growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results